Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa C Iacono

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Cancer Chemotherapy and Biological Response Modifiers|September 2, 2004
Topoisomerase I interactive agentsP Kellie Turner, Lisa C Iacono, Clinton F Stewart
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
The importance of pharmacokinetic limited sampling models for childhood cancer drug developmentJ Carl Panetta, Lisa C Iacono, Peter C Adamson, et al.
Neuro-Oncology|February 8, 2006
Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastomaBurgess B Freeman, Lisa C Iacono, John C Panetta, et al.
Journal of Pediatric Hematology/Oncology|September 3, 2004
Topotecan disposition in an anephric childLisa C Iacono, Denise Adams, Alan C Homans, et al.
Pediatric Blood & Cancer|December 1, 2005
Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancerBurgess B Freeman, Pamela Hinds, Lisa C Iacono, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 31, 2002
Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detectionFeng Bai, Mark N Kirstein, Suzan K Hanna, et al.
Cancer Chemotherapy and Pharmacology|April 9, 2005
Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTICMark N Kirstein, John C Panetta, Amar Gajjar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Population pharmacokinetic analysis of topotecan in pediatric cancer patientsPaula Schaiquevich, John C Panetta, Lisa C Iacono, et al.
Cancer Chemotherapy and Pharmacology|July 28, 2005
Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in childrenP Kellie Turner, Lisa C Iacono, John C Panetta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumorsNajat C Daw, Victor M Santana, Lisa C Iacono, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cancer Chemotherapy and Biological Response Modifiers|September 2, 2004
Topoisomerase I interactive agentsP Kellie Turner, Lisa C Iacono, Clinton F Stewart
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
The importance of pharmacokinetic limited sampling models for childhood cancer drug developmentJ Carl Panetta, Lisa C Iacono, Peter C Adamson, et al.
Neuro-Oncology|February 8, 2006
Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastomaBurgess B Freeman, Lisa C Iacono, John C Panetta, et al.
Journal of Pediatric Hematology/Oncology|September 3, 2004
Topotecan disposition in an anephric childLisa C Iacono, Denise Adams, Alan C Homans, et al.
Pediatric Blood & Cancer|December 1, 2005
Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancerBurgess B Freeman, Pamela Hinds, Lisa C Iacono, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 31, 2002
Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detectionFeng Bai, Mark N Kirstein, Suzan K Hanna, et al.
Cancer Chemotherapy and Pharmacology|April 9, 2005
Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTICMark N Kirstein, John C Panetta, Amar Gajjar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Population pharmacokinetic analysis of topotecan in pediatric cancer patientsPaula Schaiquevich, John C Panetta, Lisa C Iacono, et al.
Cancer Chemotherapy and Pharmacology|July 28, 2005
Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in childrenP Kellie Turner, Lisa C Iacono, John C Panetta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumorsNajat C Daw, Victor M Santana, Lisa C Iacono, et al.
Pageof 2